|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Department of Pathology and Laboratory
Medicine, Institute for Medicine and Engineering, and Department of
Bioengineering, University of Pennsylvania, Philadelphia, and the
Rosenstiel Basic Medical Sciences Research Center and Department of
Biology, Brandeis University, Waltham, MA.
The bcr/abl fusion in chronic myelogenous leukemia (CML) creates a
chimeric tyrosine kinase with dramatically different properties than
intact c-abl. In P210 bcr/abl, the bcr portion includes a coiled-coil
oligomerization domain (amino acids 1-63) and a grb2-binding site at
tyrosine 177 (Tyr177) that are critical for fibroblast transformation, but give variable results in other cell lines. To
investigate the role of the coiled-coil domain and Tyr177 in promoting
CML, 4 P210 bcr/abl-derived mutants containing different bcr domains
fused to abl were constructed. All 4 mutants, The P210 bcr/abl (P210) fusion oncoprotein results
from the t(9;22) chromosomal translocation.1 The c-abl
protein is a tightly regulated tyrosine kinase that is predominantly
nuclear in hematopoietic cells, whereas bcr is cytoplasmic with
serine/threonine kinase activity.2,3 The t(9;22) results
in a chimeric protein in which the first exon of c-abl is replaced by
truncated bcr that not only creates a novel cytoplasmic fusion
protein but also places transcriptional control of abl expression under
the bcr promoter. The overwhelming majority of humans with chronic
myelogenous leukemia (CML) have the P210 fusion protein; however, a
small minority express either a P190 or a P230 bcr/abl fusion
protein.4,5 All 3 isoforms are composed of identical c-abl
C-terminal coding sequences but differ in their
NH2-terminal bcr sequences. P190 contains bcr exon
1, P210 contains bcr exons 1-12/13, and P230 contains exons
1-19.4 Although these 3 different bcr/abl fusion proteins
have different propensities to cause CML, acute lymphocytic leukemia
(ALL), and neutrophilic CML, each has been identified in
patients with CML. The association of each of these 3 different bcr/abl
fusion proteins with CML suggests that the minimal bcr sequences
required to induce chronic-phase CML are located within exon 1. This
possibility is supported by results from retroviral transduction
studies in mice in which P190, P210, and P230 cause a similar
myeloproliferative disease (MPD) when introduced into murine
hematopoietic stem cells6 (J.P.M., W.S.P., unpublished observations, August 1998).
The P210 fusion oncoprotein contains multiple functional
domains/motifs. The c-abl protein contains SH3 and SH2 domains,
tyrosine kinase activity, motifs for nuclear localization, DNA and
actin binding, as well as docking sites for several adapter
molecules.3,7,8 The bcr region of P210 includes a
coiled-coil (C-C) oligomerization domain (amino acids 1-63), followed
by a grb2-binding site at Tyr177, an SH2 binding domain (amino acids
192-214 and 298-413), a serine/threonine kinase domain (amino acids
299-413), Dbl/CDC24 guanine-nucleotide exchange factor homology domain,
pleckstrin homology domain, and binding sites for the Abl SH2 domain
and several other molecules including 14-3-3.2,9-12 The
common bcr region between P190, P210, and P230 contains the C-C domain,
Tyr177, SH2-binding domain, and serine/threonine kinase domain.
Numerous studies have been performed to understand the molecular
mechanisms of bcr/abl-induced transformation and multiple signaling
pathways activated by this chimeric tyrosine kinase have been
identified. Most of these studies relied on fibroblast transformation
or cytokine-independent growth of transformed hematopoietic cell
lines.13 Although all assays suggest that abl tyrosine kinase activity is essential for bcr/abl transformation, the importance of other domains has been equivocal depending on the assay. For example, the Tyr177 motif in bcr is essential for fibroblast
transformation, yet dispensable for rescue of factor-dependent
hematopoietic cells.10,14,15 It is unclear which of these
in vitro assays is more relevant to CML because neither replicates the
MPD that is the hallmark of this disease.
To overcome the limitations of assays that may not be relevant to CML,
we and others have developed a murine model in which mice receiving
P210-transduced bone marrow (BM) cells develop a fatal
MPD.6,16-18 The MPD occurs within 21 days of bone marrow transplantation (BMT) in 100% of recipient mice. The development of a
100% efficient reproducible murine model provides the basis for in
vivo structure function analysis of bcr/abl. In this report, we focus
on several domains within bcr that are necessary for induction of the
murine MPD. In particular, we have focused on the C-C domain (amino
acids 1-63) and Tyr177 of Bcr. The importance of these domains to the
development of the MPD is unclear because results from in vitro studies
have been ambiguous. To study the role of the C-C domain and Tyr177
grb2-binding site in the pathogenesis of CML, we assayed 4 different
bcr/abl mutant proteins in our in vivo murine model. In vitro studies
showed that neither the N-terminal C-C domain nor Tyr177 was required
for in vitro kinase activity or rescue of factor-dependent
hematopoietic cell lines. In contrast, both regions were required to
induce a murine MPD. These findings suggest that the specific signaling
pathways activated by both the N-terminal C-C domain and Tyr177 are
required for the MPD.
Plasmid constructs
Immunokinase assay
Coimmunoprecipitation and immunoblotting Each construct was transfected into Bosc cells as described above.17 Two days after transfection, cells were washed with cold PBS and then lysed in 1 times NP-40 lysis buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 1% NP-40, protease inhibitors mentioned above). A small aliquot of the whole lysis was kept and mixed with SDS loading buffer. The remaining cell lysis supernatant was then immunoprecipitated with anti-Abl antibody 24-11 and the immunoprecipitate was washed 4 times with 1 times NP-40 lysis buffer. After the last wash, an equal volume of SDS loading buffer was added to obtain the final volume of 50 µL. The sample was then subjected to SDS-PAGE and transferred to nitrocellulose membranes, and the protein blots were probed with 24-11 or -grb2 antibody (Transduction Laboratories, Lexington, KY). The whole cell lysis mentioned
above was immunoblotted with the same grb2 antibody. For mouse tissue and FL5.12 immunoblots, the cell suspension (2 × 107
cells/mL) was kept in cold PBS with the protease inhibitors described above. An equal volume of 2 times SDS loading buffer was added and the
lysate was boiled for 5 minutes. The lysate was sonicated and cleared
by centrifugation. The cell lysate was resolved by SDS-PAGE and
transferred to nitrocellulose membranes. Protein blots were probed with
anti-abl antibody 24-11 or antiphophotyrosine antibody (PY20;
Transduction Laboratories) or 4G10 (Upstate Biotechnology, Lake
Placid, NY).
The protocol for investigating the interaction between P210 and bcr was kindly provided by Rick Van Etten (K. Smith, R. Van Etten, written personal communication, August 18, 2001). Briefly, proteins were coexpressed using an in vitro transcription/translation (IVT) reticulocyte lysate system (Promega) and the products were labeled with 35S-methionine. Then, 40 µL of the IVT products was mixed with 460 µL c-Abl lysis buffer (10 mM Tris-HCL, pH 7.6, 50 mM NaCl, 5 mM EDTA, 30 mM sodium pyrophosphate,1% Triton X-100, 1 mM PMSF, 1% aprotinin, 25 mM NaF, 1 mM NaVO4) and precleared with protein G agarose at 4°C for 1 hour. The precleared supernatant was combined with 1 µg anti-His monoclonal antibody (mAb; Invitrogen) and allowed to immunoprecipitate overnight at 4°C, and subsequently precipitated with protein G agarose for 1 hour, followed by washing (3 times) with 1 mL c-abl lysis buffer. The agarose was resuspended in 20 µL SDS loading buffer, boiled, and subjected to 7% SDS-PAGE. The SDS-PAGE gel was dried and subjected to autoradiography. Retrovirus preparation and BM infection/BMT Protocols were performed as previously described.17 All retroviral supernatants were titered before use, stored at 80°C, and normalized as previously described.17
Briefly, retroviral supernatants were harvested from transiently
transfected Bosc23 cells. The retroviral supernatants were stored at
80°C and a 100-µL test aliquot was thawed and used to transduce
2 × 105 NIH3T3 cells that had been plated on a 60-mm
dish the previous afternoon. The NIH3T3 cells were trypsinized 48 hours
after transduction and analyzed by fluorescence-activated cell sorting
(FACS) for green fluorescent protein (GFP) expression. All retroviral
supernatants used in the experiments reported in this manuscript gave
between 20% and 30% GFP-expressing cells per 100 µL retroviral
supernatant (data not shown). We have previously shown that this
infectious titer is in the linear range and that infectious titers of
20% allow P210 bcr/abl to induce an MPD in 100% of mice receiving transduced BM cells.17 All BM transductions were performed
by spinoculation in the absence of producer cells. All in vivo
experiments were repeated at least once using at least 2 different
preparations of retroviral supernatant.
Flow cytometry and DNA analysis These were performed as previously described.17
All 4 bcr/abl mutants demonstrate activated tyrosine kinase activity To determine the requirement for the C-C and Tyr177 bcr domains in the pathogenesis of the murine MPD, 4 P210-derived mutants were constructed. Based on previous studies, we hypothesized that the NH2-terminal C-C domain or the C-C domain plus the grb2-binding site would be sufficient for MPD induction. To test this hypothesis, 4 mutants that contained identical P210-derived c-abl sequences, preceded by different bcr mutant sequences, were assembled (Figure 1A). To assay the contribution of the C-C domain directly, 1-63 bcr/abl and (1-63) bcr/abl were constructed.
The former appends amino acids 1-63 of bcr to the second exon of c-abl,
whereas the latter contains all of P210 except amino acids 1-63 of bcr.
The role of Tyr177 was assayed by mutating this residue to
phenylalanine (Tyr177Phe bcr/abl). A fourth mutant ([1-210] bcr/abl)
fuses the N-terminal 210 amino acids of bcr to the c-abl second exon
and contains both the C-C domain and Tyr177. This region lacks 717 amino acid from P210. The mutant cDNAs were cloned into the MigR1 retroviral vector that coexpresses GFP as a surrogate
marker.17 Transient expression in Bosc23 cells confirmed
that proteins of the correct molecular weight were produced (Figure 1B
and data not shown).
Oncogenic activity of bcr/abl requires its activated tyrosine
kinase.18 To determine the tyrosine kinase activity of
each mutant, transiently expressed bcr/abl mutants were directly
immunoprecipitated from host Bosc23 cells and an in vitro immunokinase
assay was performed using exogenous GST-Crk as a
substrate.21,22 Each mutant exhibited elevated and
approximately equal tyrosine kinase activity in vitro, as measured by
GST-Crk phosphorylation (Figure 1B). The weak phosphorylation of
GST-Crk in the MigR1 lysate (immunoprecipitated with 24-11) is likely
due to endogenous c-abl activity (Figure 1B). The specificity of the
assay was shown by using a Crk deletion mutant, Crk 212, that lacks
Tyr221 and is unable to be phosphorylated by the in vitro kinase assay
(Figure 1B).20 In contrast to their equivalent
phosphorylation of GST-Crk, Tyr177Phe bcr/abl, (1-63) bcr/abl, and
The ability of Tyr177 is required for grb2 binding Two of the mutant bcr/abl fusion proteins, (1-210) bcr/abl and(1-63) bcr/abl, and wild-type P210 contain Tyr177. Bcr/abl binds
grb2 resulting in ras activation and fibroblast
transformation.10,14,15 To assay the ability of our
mutants to bind endogenous grb2, each mutant was transfected into
Bosc23 cells and coimmunoprecipitations with the -Abl antibody,
24-11, were performed (Figure 1D). As expected, only P210, (1-210)
bcr/abl, and (1-63) bcr/abl associated with grb2 in vivo, and both
of these mutants were similar to wild-type P210 in their ability to
autophosphorylate Tyr177 and bind grb2. In contrast, the mutants
lacking Tyr177 did not associate with grb2 (Figure 1D).
Neither the coiled-coil domain nor Tyr177 is required for factor-independent growth We assayed the ability of each mutant to confer factor-independent growth to FL5.12 cells, which require interleukin 3 (IL-3) for survival and growth. Because the MigR1 retroviral vector expresses a bicistronic transcript containing the bcr/abl construct and GFP, transduced cells can be identified by GFP expression. FL5.12 cells were transduced by each of the 4 bcr/abl mutants so that roughly equivalent cell percentages were GFP+ by 40 hours after transduction in the presence of IL-3 (Figure 2A). IL-3 was then withdrawn, and by 64 hours later, more than 95% of cells receiving each of the bcr/abl mutants or P210 were GFP+, whereas the MigR1-transduced cells died (Figure 2A). Cell lysates were prepared and examined for bcr/abl expression and tyrosine phosphorylation (Figure 2B). Western blotting confirmed the expression of P210 and mutant proteins and showed that all of the bcr/abl-expressing cells had elevated phosphotyrosine levels compared to parental FL5.12 cells cultured in IL-3-containing media. Although difficult to draw conclusions about specific protein phosphorylation, the phosphotyrosine levels appeared similar between P210 and each mutant, with the exception of(1-63) bcr/abl, which appears to exhibit slightly less phosphotyrosine activity. Nevertheless, the
activity of (1-63) bcr/abl is still markedly elevated relative to
the negative control, and at this low level of resolution, similar sets
of target proteins are phosphorylated by wild-type P210 and all 4 mutants. In parallel experiments, P210 and each of the 4 mutants
maintained growth of FL5.12 cells in the absence of IL-3 and the growth
rates of the different factor-independent populations were similar
(data not shown). Growth factor withdrawal produced similar results
after transduction of the IL-3-dependent cell lines 32D and Ba/F3 with
each mutant (data not shown).
(1-210) bcr/abl induces MPD, in association with B-ALL To determine the effects of the bcr/abl mutants in vivo, titer-matched retroviral supernatants were used to transduce 5-fluorouracil (FU)-treated BM cells that were subsequently transferred to lethally irradiated recipients. Although MigR1 mice remained healthy for at least 1 year, 100% of P210 mice developed a fatal MPD within 3 weeks after BMT (Figures 3 and 4A; Table 1). Using this mouse model, we first assayed (1-210) bcr/abl that contains both the C-C domain and Tyr177. One hundred percent of mice receiving (1-210) bcr/abl developed a rapidly fatal hematopoietic disease by approximately 5 weeks after BMT (Table 1). The disease latency was significantly longer (P = .0125) than that in P210 mice (Figure 3). Similar to wild-type P210 mice, the mice became cachectic, exhibited decreased activity and poor grooming, and developed elevated white blood cell (WBC) counts, suggestive of leukemia (Table 1). The peripheral blood smears of 4 of 15 mice were predominantly comprised of mature granulocytes and very similar to wild-type P210 mice17 (and data not shown). In 11 of 15 mice receiving transplants, however, lymphoblasts were present in conjunction with an excess of granulocytes (not shown).
Immunophenotyping was performed to further characterize the disease
process in the (1-210) bcr/abl mice. The majority of circulating cells
in all P210 and (1-210) bcr/abl mice were GFP+ (Figure
4A,B). In 4 of 15 mice, the majority of cells were
Gr-1+/Mac1+ consistent with mature granulocytes
(Figure 4B). Eleven of 15 (1-210) bcr/abl mice had high numbers of both
circulating Gr-1+/Mac1+ granulocytes and pre-B
lymphoblasts (Figure 4C). Consistent with previous findings, the
absolute numbers of circulating GFP The (1-210) bcr/abl mice were killed when symptomatic. The pathologic changes in the 4 mice without circulating lymphoblasts were nearly identical to the pathologic changes observed in wild-type P210 mice and included hepatosplenomegaly and pulmonary hemorrhage with extensive infiltration of these organs and BM by mature myeloid cells. There was also extensive extramedullary hematopoiesis in the spleen and liver. Lymphadenopathy was minimal. The gross pathologic changes in the 11 mice with circulating lymphoblasts and MPD were similar, including the lack of lymphadenopathy; however, the spleen, BM, liver, and lungs of these mice showed both infiltrating mature myeloid cells and lymphoblasts (not shown). The disease in the (1-210) bcr/abl mice suggested this construct was sufficient to induce an MPD; however, in contrast to P210, there were also circulating lymphoblasts in the great majority of mice. To further understand the disease process, cells from the spleen were transplanted into sublethally irradiated secondary recipients (Table 1). Secondary recipients of BMT from P210 mice gave rise to an MPD in the minority of secondary recipients and T-cell lymphomas in the majority (and data not shown).17 None of the secondary recipients of P210 BM or spleen cells developed B-ALL. Transfer of spleen cells from four (1-210) bcr/abl mice into secondary recipients (n = 11) gave rise to pre-B-ALL in all recipients, even though one of the 4 primary mice had no evidence of circulating B lymphoblasts (Table 1). Secondary recipients from 2 mice had both B- and T-ALL; and one secondary recipient developed the triad of B-ALL, T-ALL, and MPD (Figure 4D and Table 1). The high numbers of circulating pre-B lymphoblasts and their transplantability suggest that the circulating B lymphoblasts in the primary mice were leukemic. Both (1-63) bcr/abl and (1-63) bcr/abl showed no evidence of disease at this time. To determine if the mutant constructs were expressed and if there were subtle pathologic changes, 4 healthy-appearing (1-63) bcr/abl mice were killed at various times
between 35 and 42 days. Despite evidence that the mutant (1-63) bcr/abl
construct was expressed and tyrosine phosphorylated a similar set of
proteins (Figure 5A,B), none of the
hallmarks of the P210 disease were present, including lack of
hepatosplenomegaly, pulmonary hemorrhage, or infiltration of the organs
by myeloid cells. Two abnormalities in the (1-63) bcr/abl mice were the
presence of circulating GFP+ pre-B cells and an increase in
the percentage of circulating granulocytes (Figure
6A and not shown). However, unlike
wild-type P210 and (1-210) bcr/abl mice, these changes occurred in the
presence of normal WBC counts. Furthermore, neither the circulating
pre-B cells nor the granulocytes expanded and they did not appear to contribute to morbidity in these mice.
Between 14 and 25 weeks, 7 of 9 of the (1-63) bcr/abl mice developed lethargy and cachexia, and were killed (Table 1). All of the ill mice had normal WBC counts and lacked hepatosplenomegaly. Among them, 6 mice had an atypical immature GFP+ T-cell population within the thymus, consistent with T-ALL (Figure 6B). One of the ill-appearing mice had a pleural effusion without evidence of malignancy. The remaining 2 mice appeared healthy at 25 weeks after BMT. These results show that the C-C domain of bcr fused to abl does not induce MPD but causes a T-cell malignancy in 67% of primary recipients of BMT by 25 weeks after BMT. To further assess the role of the C-C domain, the
Mutation of Tyr177 inhibits MPD induction To further analyze the role of bcr in MPD induction, we assayed the Tyr177Phe mutant, which is unable to bind grb2. Similar to the C-C mutants, these mice were healthy at the time that the wild-type P210 or (1-210) bcr/abl mice became ill. Between 9 and 20 weeks after BMT, these mice developed symptoms of cachexia and lethargy. Eleven of 12 analyzed mice developed T-cell lymphoma characterized by an expanding mass of immature CD4+CD8+GFP+ T cells arising in either the thymus or abdomen (Table 1 and Figure 8). None of the 12 mice developed a disease similar to that in the wild-type P210 mice. One mouse developed splenomegaly with increased granulocytes in this organ; however, the WBC count of this mouse was normal and there was no infiltration of either the liver or lungs by GFP+ granulocytes (Table 1).
Analysis of proviral integration and tumor clonality Hybridization analysis showed that all mice contained intact proviral DNA (data not shown). The number of proviral integrations varied. In the wild-type P210 mice, more than 10 proviral integrations were present in some mice, whereas other mice had fewer proviral integrations (Figure 9A and not shown). Our previous results showed that the number of proviral integrations did not correlate with disease development, because some mice developing MPD had only a single proviral integrant.17 Most of the mutant mice had fewer than 5 proviral integrations. Significantly, some of the mice that were killed when healthy showed many proviral integrations (Figure 9A, lane 11) and tumors from two (1-63) bcr/abl mice showed at least 8 proviral integrations in a single clone. Analysis of the T-cell neoplasms that developed in the (1-63) bcr/abl,(1-63) bcr/abl, and Tyr177Phe
bcr/abl mice showed that they contained a predominant clone (Figure
9B). This suggests that events in addition to expression of the mutated
bcr/abl protein are necessary for tumor development in these
mice.
Our results demonstrate that both the
NH2-terminal C-C domain and Tyr177 from bcr are
required for MPD induction by the bcr/abl fusion oncoprotein. In
contrast, neither the C-C domain nor Tyr177 alone is essential for
bcr/abl tumorigenesis. Three mutants, (1-63) bcr/abl, The (1-210) bcr/abl mutant, which contains both the C-C domain and Tyr177, induced an MPD with short latency in all recipients; however, most mice also had a coexistent B-ALL. There are more than 700 amino acids between Tyr177 and the carboxy-terminus of bcr in P210, which includes sites for binding to Abl SH2 and other proteins, such as 14-3-3.11,12 The emergence of B-ALL in combination with the MPD suggests that sequences within this region either promote a more rapid expansion of the myeloid population or suppress expansion of the pre-B population. The (1-63) bcr/abl mutant also elicited a transient expansion of immature B cells; however, B-ALL did not develop in these mice, suggesting that sequences between amino acids 63 and 210 are also necessary for B-ALL induction. Both the structure of the bcr/abl fusion protein and the cells in which the fusion protein is expressed have been implicated in determining the phenotype of the murine disease.6,23 All mice receiving P230, P210, or P190 bcr/abl-transduced 5-FU-treated BM cells developed MPD6 (J.P.M., W.S.P., unpublished observations, August 1998), whereas transfer of these fusion proteins into non-5-FU-treated BM results in induction of pre-B ALL by P190 and induction of a macrophage tumor by P210 and P230.6 These results suggest that transduction of hematopoietic stem cells, which are greatly enriched in 5-FU-treated BM,24 are required for MPD induction. Because our current studies used retroviral supernatants with equivalent infectious titers and transduced 5-FU-treated BM cells, the differences in disease phenotypes that we observe are likely to result from structural differences between the fusion proteins themselves, rather than differences in the transduced target cells or differences in infectious titers. Two different models may explain the phenotypic differences in disease caused by the different bcr/abl mutant proteins. One model proposes that the regions of bcr act in cis on the abl tyrosine kinase resulting in different levels of dysregulated tyrosine kinase activity that ultimately determines the disease phenotype. An alternative model is that proteins interacting in trans initiate signaling cascades that act in synergy with the dysregulated tyrosine kinase. Our data favor the latter hypothesis because the phosphotyrosine pattern of the different mutants is comparable to wild-type P210 both in vitro and in vivo. However, as noted in the results, it is possible that there are subtle differences in kinase activity and tyrosine phosphorylation that we have failed to discern. The In contrast to the results reported here, a recent report from Zhang et al19 found that the oligomerization domain fused to abl was sufficient to induce a MPD in mice receiving transduced BM cells. One potential explanation for the different findings is that their oligomerization domain consisted of the first 77 amino acids of bcr, whereas we used the first 63 amino acids. Their rationale for the additional 14 amino acids was that the first 77 amino acids of bcr form a globular structure. An alternative explanation is that technical differences, due to variations in transduction protocols or retroviral titers, may account for the observed phenotypic differences. It is important to note that although the CC-abl mutant of Zhang and coworkers19 induced some aspects of an MPD disease, they pointed out that this MPD differed from that induced by P210 bcr/abl in several important aspects, including (1) failure to induce a fatal disease in the majority of mice, (2) an extended latency (mean = 138 days), (3) a transient MPD phase that occurred in less than 100% of recipients, and (4) the mice did not develop pulmonary hemorrhages. Thus, both our results and those of Zhang et al19 are in agreement in showing that the C-C domain is required to cause the rapid and fatal MPD induced by wild-type P210 bcr/abl. A direct interaction between bcr/abl and grb2 through Tyr177 is a proximal event in ras activation and is required for fibroblast transformation, but not IL-3-independent growth.10,15 Another group recently reported that Tyr177Phe is defective in MPD induction, and instead induces T-cell tumors in most mice.29 In contrast to our results, they also observed B-ALL induction in some mice and some features of the MPD in mice with T-cell lymphomas.29 Differences in retroviral vectors or titers, transduction conditions, or exposure of mice to pathogens may account for the subtle differences between our results and those of Million and Van Etten.29 Moreover, the elevated WBC counts and high neutrophil counts observed in several of Million and Van Etten's29 Tyr177Phe bcr/abl mice were associated with a relatively benign condition and distinctly different from wild-type P210 bcr/abl disease, in which 100% of the mice die within 21 days from a fatal MPD. Both Million and Van Etten's29 and our results, as well as the recent report of Zhang et al,19 show that the Tyr177Phe bcr/abl mutant is markedly deficient in MPD induction. Coexpression of another adapter protein, shc, rescues the ability of Tyr177Phe to transform fibroblasts15 and our model provides an opportunity to test whether shc can also rescue MPD induction. In addition, studies of the tel/platelet-derived growth factor receptor (PDGFR) fusion found in some patients with chronic myelomonocytic leukemia show that mutating specific tyrosine residues in the PDGFR portion, including those that mediate grb2 interaction, changes both the latency and phenotype of disease in a murine model.30 Our results show that the role of bcr in CML induction is not simply to activate the abl tyrosine kinase. Consistent with this observation, mice receiving v-abl-transduced BM cells failed to develop an MPD, but instead, developed B-ALL or mast cell tumors.29,31,32 It is important to note that previous descriptions of MPD induction by v-abl33,34 were most likely a reactive process because the expanded polymorphonuclear cells did not contain the bcr/abl provirus.34 Our results show that mutations within bcr itself, some of which have no effect on bcr/abl tyrosine kinase activity, have profound effects on disease phenotype, latency, and penetrance. The signaling pathways affected by the Tyr177Phe mutation are likely to be those that couple grb2 to ras signaling. In contrast, the primary contribution of the oligomerization domain may be to direct proper cytoskeletal interactions. The mechanism by which this occurs is poorly understood. Nevertheless, our results show bcr amino acids 1-63 are required for MPD induction, but dispensable for T-ALL induction. Finally, our results demonstrate the importance of using relevant assays to study bcr/abl leukemogenesis. Neither rescue of factor-dependent hematopoietic cell lines nor in vitro kinase activity revealed significant differences between wild-type P210 and the 4 bcr/abl mutant proteins. In contrast, our BMT model showed significant differences between wild-type bcr/abl and the 4 mutants. The ability to use a murine model that is both relevant to CML and provides a sensitive readout should be extremely useful in further dissecting the pathways that lead from bcr/abl to CML.
We thank Martin Carroll, Alan Gewirtz, and members of the Pear laboratory for critical reading of the manuscript. We thank Mark Lemmon, Xiaomeng Long, Ann Marie Pendergast, Bruce Mayer, and Rick Van Etten for providing reagents and protocols and members of the University of Pennsylvania mouse and flow cytometry facilities. W.S.P. also acknowledges the mentorship of David Baltimore in whose laboratory these studies were initiated.
Submitted October 31, 2001; accepted November 16, 2001.
Supported by RO1 grants from the National Institutes of Health (National Cancer Institute) and Scholar Awards from the Leukemia and Lymphoma Society to R.R. and W.S.P.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Warren S. Pear, University of Pennsylvania, 611 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104-6160; e-mail: wpear{at}mail.med.upenn.edu.
1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1197-1200. 2. Maru Y, Witte ON. The BCR gene encodes a novel serine/threonine kinase activity within a single exon. Cell. 1991;67:459-468[CrossRef][Medline] [Order article via Infotrieve]. 3. Wang JY. Abl tyrosine kinase in signal transduction and cell-cycle regulation. Curr Opin Genet Dev. 1993;3:35-43[CrossRef][Medline] [Order article via Infotrieve].
4.
Melo JV.
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.
Blood.
1996;88:2375-2384
5.
Sawyers CL.
Chronic myeloid leukemia.
N Engl J Med.
1999;340:1330-1340
6.
Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA.
The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
J Exp Med.
1999;189:1399-1412
7.
Van Etten RA, Jackson PK, Baltimore D, Sanders MC, Matsudaira PT, Janmey PA.
The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity.
J Cell Biol.
1994;124:325-340 8. Van Etten RA. Cycling, stressed-out and nervous: cellular functions of c-Abl. Trends Cell Biol. 1999;9:179-186[CrossRef][Medline] [Order article via Infotrieve].
9.
McWhirter JR, Galasso DL, Wang JY.
A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
Mol Cell Biol.
1993;13:7587-7595 10. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adapter protein. Cell. 1993;75:175-185[CrossRef][Medline] [Order article via Infotrieve]. 11. Pendergast AM, Muller AJ, Havlik MH, Maru Y, Witte ON. BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner. Cell. 1991;66:161-171[CrossRef][Medline] [Order article via Infotrieve].
12.
Reuther GW, Fu H, Cripe LD, Collier RJ, Pendergast AM.
Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family.
Science.
1994;266:129-133 13. Ghaffari S, Daley GQ, Lodish HF. Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays. Leukemia. 1999;13:1200-1206[CrossRef][Medline] [Order article via Infotrieve]. 14. Cortez D, Kadlec L, Pendergast AM. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol Cell Biol. 1995;15:5531-5541[Abstract]. 15. Goga A, McLaughlin J, Afar DE, Saffran DC, Witte ON. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 1995;82:981-988[CrossRef][Medline] [Order article via Infotrieve].
16.
Daley GQ, Van Etten RA, Baltimore D.
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Science.
1990;247:824-830
17.
Pear WS, Miller JP, Xu L, et al.
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
Blood.
1998;92:3780-3792
18.
Zhang X, Ren R.
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Blood.
1998;92:3829-3840
19.
Zhang X, Subrahmanyam R, Wong R, Gross AW, Ren R.
The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.
Mol Cell Biol.
2001;21:840-853 20. Feller SM, Knudsen B, Hanafusa H. c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J. 1994;13:2341-2351[Medline] [Order article via Infotrieve].
21.
Konopka JB, Witte ON.
Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products.
Mol Cell Biol.
1985;5:3116-3123 22. Kharbanda S, Ren R, Pandey P, et al. Activation of the c-Abl tyrosine kinase in the stress response to DNA damaging agents. Nature. 1995;376:785-788[CrossRef][Medline] [Order article via Infotrieve]. 23. Pear WS. Signaling in leukemia: which messenger to kill? J Clin Invest. 2000;105:419-422[Medline] [Order article via Infotrieve].
24.
Randall TD, Weissman IL.
Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment.
Blood.
1997;89:3596-3606
25.
Cohen C, Parry DA.
26. Golub TR, Goga A, Barker GF, et al. Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia. Mol Cell Biol. 1996;16:4107-4116[Abstract]. 27. Minucci S, Maccarana M, Cioce M, et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell. 2000;5:811-820[CrossRef][Medline] [Order article via Infotrieve]28
28.
Heisterkamp N, Voncken JW, Senadheera D, et al.
Reduced oncogenicity of p190 Bcr/Abl F-actin-binding domain mutants.
Blood.
2000;96:2226-2232
29.
Million RP, Van Etten RA.
The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
Blood.
2000;96:664-670 30. Tomasson MH, Sternberg DW, Williams IR, et al. Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. J Clin Invest. 2000;105:423-432[Medline] [Order article via Infotrieve]. 31. Gurish MF, Pear WS, Stevens RL, et al. Tissue-regulated differentiation and maturation of a v-abl-immortalized mast cell-committed progenitor. Immunity. 1995;3:175-186[CrossRef][Medline] [Order article via Infotrieve]. 32. Gross AW, Ren R. Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells. Oncogene. 2000;19:6286-6296[CrossRef][Medline] [Order article via Infotrieve].
33.
Kelliher MA, McLaughlin J, Witte ON, Rosenberg N.
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
Proc Natl Acad Sci U S A.
1990;87:6649-6653
34.
Scott ML, Van ERA, Daley GQ, Baltimore D.
v-abl causes hematopoietic disease distinct from that caused by bcr-abl.
Proc Natl Acad Sci U S A.
1991;88:6506-6510
35.
Pear WS, Aster JC, Scott ML, et al.
Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles.
J Exp Med.
1996;183:2283-2291
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  I. Lahortiga, C. Akin, J. Cools, T. M. Wilson, N. Mentens, D. C. Arthur, I. Maric, P. Noel, C. Kocabas, P. Marynen, et al. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion Haematologica, January 1, 2008; 93(1): 49 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kawano, M. Ito, D. Raina, Z. Wu, J. Rosenblatt, D. Avigan, R. Stone, and D. Kufe MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells Cancer Res., December 15, 2007; 67(24): 11576 - 11584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen, W.-M. Yu, H. Daino, H. E. Broxmeyer, B. J. Druker, and C.-K. Qu SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl Blood, January 15, 2007; 109(2): 778 - 785. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. H. Stover, J. Chen, C. Folens, B. H. Lee, N. Mentens, P. Marynen, I. R. Williams, D. G. Gilliland, and J. Cools Activation of FIP1L1-PDGFR{alpha} requires disruption of the juxtamembrane domain of PDGFR{alpha} and is FIP1L1-independent PNAS, May 23, 2006; 103(21): 8078 - 8083. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Zweidler-McKay, Y. He, L. Xu, C. G. Rodriguez, F. G. Karnell, A. C. Carpenter, J. C. Aster, D. Allman, and W. S. Pear Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies Blood, December 1, 2005; 106(12): 3898 - 3906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. De Keersmaecker, C. Graux, M. D. Odero, N. Mentens, R. Somers, J. Maertens, I. Wlodarska, P. Vandenberghe, A. Hagemeijer, P. Marynen, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32) Blood, June 15, 2005; 105(12): 4849 - 4852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Kharas and D. A. Fruman ABL Oncogenes and Phosphoinositide 3-Kinase: Mechanism of Activation and Downstream Effectors Cancer Res., March 15, 2005; 65(6): 2047 - 2053. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ramaraj, H. Singh, N. Niu, S. Chu, M. Holtz, J. K. Yee, and R. Bhatia Effect of Mutational Inactivation of Tyrosine Kinase Activity on BCR/ABL-Induced Abnormalities in Cell Growth and Adhesion in Human Hematopoietic Progenitors Cancer Res., August 1, 2004; 64(15): 5322 - 5331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Million, N. Harakawa, S. Roumiantsev, L. Varticovski, and R. A. Van Etten A Direct Binding Site for Grb2 Contributes to Transformation and Leukemogenesis by the Tel-Abl (ETV6-Abl) Tyrosine Kinase Mol. Cell. Biol., June 1, 2004; 24(11): 4685 - 4695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Beissert, E. Puccetti, A. Bianchini, S. Guller, S. Boehrer, D. Hoelzer, O. G. Ottmann, C. Nervi, and M. Ruthardt Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571 Blood, October 15, 2003; 102(8): 2985 - 2993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Wertheim, S. A. Perera, D. A. Hammer, R. Ren, D. Boettiger, and W. S. Pear Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development Blood, September 15, 2003; 102(6): 2220 - 2228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Pawson and P. Nash Assembly of Cell Regulatory Systems Through Protein Interaction Domains Science, April 18, 2003; 300(5618): 445 - 452. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. V. Melo, T. P. Hughes, and J. F. Apperley Chronic Myeloid Leukemia Hematology, January 1, 2003; 2003(1): 132 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M.-Y. Ho, M. H.-H. Nguyen, J. K. Dierov, K. M. Badger, B. K. Beattie, P. Tartaro, R. Haq, B. W. Zanke, M. P. Carroll, and D. L. Barber TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways Blood, July 30, 2002; 100(4): 1438 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Wertheim, K. Forsythe, B. J. Druker, D. Hammer, D. Boettiger, and W. S. Pear BCR-ABL-induced adhesion defects are tyrosine kinase-independent Blood, May 13, 2002; 99(11): 4122 - 4130. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-[32P] ATP
for 5 minutes at room temperature. The kinase reaction was
terminated by adding 1 mL cold phosphate-buffered saline (PBS) and
washed 5 times with cold PBS. After the final wash, an equal volume of
2 times SDS buffer was added to obtain the final volume of 50 µL for
SDS-PAGE. The SDS-polyacrylamide gels were then analyzed by autoradiography.
.
and GFP+
populations are shown in the upper right panel. The lower panel pairs
are divided into GFP
1 probe to detect TCR
rearrangement status as previously described.
HindIII molecular weight marker is shown on the
left.
a widespread motif in proteins.
TIBS.
1986;11:245-248.